ALung to Pursue SFDA Approval of Hemolung RAS in China
Under the terms of the agreement, Curative Medical will supervise a clinical trial of the Hemolung RAS which provides Respiratory Dialysis® for patients in acute respiratory failure. ALung will contribute all of the necessary equipment and protocol support for the duration of the trial. Commercial distribution of the device in China is expected following receipt of SFDA approval.
“There is a clear clinical need for the Hemolung RAS in China,” said Peter DeComo, Chairman and CEO of ALung. “Over 65 million Chinese suffer from chronic obstructive pulmonary disease, primarily due to high rates of tobacco use. When patients with advanced COPD suffer sudden worsening of their symptoms, known as an acute exacerbation, they will sometimes require intubation and invasive mechanical ventilation as a lifesaving measure. With the Hemolung RAS, we can actually help these patients avoid intubation, allowing them to remain awake, communicate, and participate in their own rehabilitation.”
ALung’s agreement with Curative Medical was facilitated by David Iwinski of Blue Water Growth, a global business consulting firm. “We found a good partner in Curative given their strong position as leading developer and distributor of cardiopulmonary products in China,” said Nicholas Kuhn, President and Chief Business Officer of ALung. “Blue Water Growth was instrumental to the formation of this partnership, helping us successfully navigate what was a rather complicated process.”
Earlier in 2013, ALung was granted a Health Canada License and the CE Mark, allowing the Hemolung RAS to be marketed in Canada and throughout the European Union.
Published on : Wed, 29 May 2013
Print as PDF
NovaPort cannulas: The safe access to the vascular system. NovaPort® twin double lumen cannulas are specifically developed for veno-venous vascular access. NovaPort one single lumen cannulas are specifically developed for the percutaneous connection (KU)...
Medos hemofilters pro are used for efficient and gentle hemofiltration during extracorporal circulation.Medos hemofilters pro do not need to be pre-flushed and can be used immediately. This guarantees a safe and quick hemofiltration.
medos customized tubing sets have been individually designed, so that all customer requirements, depending on application and need can be realized. Furthermore tubing sets can be refined by rheoparin or x.eed coating. Customized and standard tubing sets...